Celldex Therapeutics EPS - Earnings per Share 2006-2021 | CLDX

Celldex Therapeutics eps - earnings per share from 2006 to 2021. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Celldex Therapeutics Annual EPS
2020 $-2.02
2019 $-3.51
2018 $-14.48
2017 $-10.86
2016 $-18.99
2015 $-19.64
2014 $-19.79
2013 $-15.29
2012 $-15.29
2011 $-16.94
2010 $-1.20
2009 $-27.59
2008 $-50.08
2007 $-27.14
2006 $-32.23
2005 $-43.93
Celldex Therapeutics Quarterly EPS
2021-09-30 $-0.45
2021-06-30 $-0.34
2021-03-31 $-0.42
2020-12-31 $-0.43
2020-09-30 $-0.36
2020-06-30 $-0.50
2020-03-31 $-0.73
2019-12-31 $-0.52
2019-09-30 $-0.75
2019-06-30 $-0.84
2019-03-31 $-1.40
2018-12-31 $0.46
2018-09-30 $-0.66
2018-06-30 $-1.67
2018-03-31 $-12.61
2017-12-31 $-0.22
2017-09-30 $-3.00
2017-06-30 $-3.45
2017-03-31 $-4.20
2016-12-31 $-4.60
2016-09-30 $-4.35
2016-06-30 $-4.80
2016-03-31 $-5.25
2015-12-31 $-4.95
2015-09-30 $-4.80
2015-06-30 $-4.95
2015-03-31 $-4.95
2014-12-31 $-5.40
2014-09-30 $-4.65
2014-06-30 $-4.80
2014-03-31 $-4.95
2013-12-31 $-3.90
2013-09-30 $-4.35
2013-06-30 $-3.60
2013-03-31 $-3.45
2012-12-31 $-4.05
2012-09-30 $-3.75
2012-06-30 $-3.45
2012-03-31 $-4.05
2011-12-31 $-4.20
2011-09-30 $-4.05
2011-06-30 $-4.05
2011-03-31 $-4.65
2010-12-31 $10.65
2010-09-30 $-4.20
2010-06-30 $-4.50
2010-03-31 $-3.15
2009-12-31 $-5.25
2009-09-30 $-6.75
2009-06-30 $-8.25
2009-03-31 $-7.35
2008-12-31 $-7.05
2008-09-30 $-7.35
2008-06-30 $-10.05
2008-03-31 $-32.83
2007-12-31 $-7.50
2007-09-30 $-7.35
2007-06-30 $-4.95
2007-03-31 $-7.35
2006-12-31 $-1.20
2006-09-30 $-12.60
2006-06-30 $-14.40
2006-03-31 $-7.20
2005-12-31 $-9.73
2005-09-30 $-10.80
2005-06-30 $-10.80
2005-03-31 $-12.60
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.361B $0.007B
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00